clinical trial · NCT04542070
A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed
ViiV Healthcare·phase3·completed·n = 687
HIV InfectionsCabotegravir TabletsCabotegravir Injectable Suspension (CAB LA)Rilpivirine TabletsRilpivirine Injectable Suspension (RPV LA)BIKTARVY Tablets (BIK)
brief summary
This study is designed to assess the antiviral activity and safety of a two-drug regimen of CAB LA + RPV LA compared with maintenance of BIK. BIKTARVY is a registered trademark of Gilead Sciences.
started
Nov 9, 2020
primary completion
Jul 13, 2022
completion
Apr 17, 2023
last updated
Jun 4, 2024
official title
A Phase IIIb, Randomized, Multicenter, Active-controlled, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Switching to Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every Two Months From a Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in HIV-1 Infected Adults Who Are Virologically Suppressed
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol